Țară: Australia
Limbă: engleză
Sursă: Department of Health (Therapeutic Goods Administration)
Pneumococcal purified capsular polysaccharides, Quantity: 2.2 microgram; Pneumococcal purified capsular polysaccharides, Quantity: 4.4 microgram
Pfizer Australia Pty Ltd
Pneumococcal purified capsular polysaccharides
Injection, suspension
Excipient Ingredients: aluminium phosphate; water for injections; polysorbate 80; Diphtheria CRM197 protein; succinic acid; sodium chloride
Intramuscular
10, 1
(S4) Prescription Only Medicine
Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children aged more than 6 weeks of age. The use of Prevenar 13 should be guided by official recommendations.
Visual Identification: Homogenous white suspension.; Container Type: Syringe; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2010-03-29
PREVENAR 13 ® _Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Prevenar 13. It does not contain all the available information. It does not take the place of talking to your doctor, clinic nurse or pharmacist. All vaccinations have benefits and risks. Your doctor or clinic nurse has weighed the risks of you or your child receiving Prevenar 13 against the benefits this vaccination is expected to provide. IF YOU HAVE ANY QUESTIONS ABOUT THIS VACCINATION, ASK YOUR DOCTOR, CLINIC NURSE OR PHARMACIST. KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. WHAT PREVENAR 13 IS USED FOR Prevenar 13 is a vaccine, which is a type of medicine that helps to protect (immunise) people from certain infectious diseases. It does this by preparing the body's defences to fight the infection, before you catch the bacteria or virus. Prevenar 13 is a mixture of the outer sugar coating (polysaccharide) from 13 different strains or serotypes of bacteria called Streptococcus pneumoniae. Each serotype is joined to a non-toxic protein to make it work more effectively. Streptococcus pneumoniae bacteria are one of the causes of • meningitis (a serious brain infection that could cause death or brain damage) • bacteraemia (infection of the blood) • pneumonia • otitis media (an ear infection that can cause pain and temporary hearing loss and may require you or your child to have an ear operation). Prevenar 13 can protect against 13 of the strains of Streptococcus pneumoniae that can cause these diseases. Prevenar 13 does not replace the need for vaccination with Haemophilus influenzae type b (Hib) or meningococcal vaccines that protect against other important causes of meningitis. You cannot catch any of the above diseases from the vaccine itself, because it is not made with live or whole bacteria. As with all vaccines, 100% protection against the above diseases cannot be guaranteed. BEFORE YOU OR YOUR CHILD IS GIVEN PREV Citiți documentul complet
Version: pfppreei10820 Supersedes: pfppreei10719 Page 1 of 34 AUSTRALIAN PRODUCT INFORMATION - PREVENAR 13 ® (PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 13-VALENT ADSORBED) 1. NAME OF THE MEDICINE Prevenar 13: Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENTS Each 0.5 mL dose contains: 2.2 µg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 µg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM 197 protein and adsorbed on aluminium phosphate (0.565 mg). For the full list of excipients, see Section 6.1 List of Excipients. 3. PHARMACEUTICAL FORM Prevenar 13 is a ready to use homogeneous white suspension for intramuscular injection (0.5 mL), supplied as a pre-filled syringe. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Active immunisation for the prevention of pneumococcal disease caused by _Streptococcus _ _pneumoniae _ serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children aged more than 6 weeks of age. The use of Prevenar 13 should be guided by official recommendations. 4.2 DOSE AND METHOD OF ADMINISTRATION The dose of Prevenar 13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults. Do not administer Prevenar 13 intravascularly or into the gluteal area. Do not administer Prevenar 13 intravenously, subcutaneously or intradermally, since the safety and immunogenicity of these routes have not been evaluated. Upon storage, a white deposit and clear supernatant can be observed. The vaccine should be well shaken to obtain a homogeneous white suspension and be inspected visually for any particulate Version: pfppreei10820 Supersedes: pfppree Citiți documentul complet